DMRA

Damora Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · EDGAR filings (CIK 1800315) · 4 signals · 1 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 55 (elevated attention) · dilution pressure low · listing risk low · governance risk elevated · runway 78.7 mo · strongest signal: Holder rights modified (Jul 20, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

55Radar · attention score (0–100)

21Dilution pressure · financing + balance sheet

27Listing risk · exchange standards

47Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.60

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language) coexists with live selling machinery (shelf effective). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Going-concern languageShelf effective

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on DMRA

Alerts

One email the morning DMRA files anything that matches your rules (types, minimum score, setups).

12-month history

Every signal and setup for DMRA back a year, not just 30 days — see how the current setup built.

Full analyst notes

What we noticed, evidence with links, what could prove us wrong, red-team caveats.

Full screener + CSV

All 985 flagged companies, same-day, sortable and exportable.

Get Pro · $18.85/mo founding rate See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$540.5Mcash + short-term investments as of Jun 30, 2026

78.7 moestimated runway (4x latest quarterly operating cash burn)

$516.1Mstockholders' equity as of Jun 30, 2026

$4.4Mpublic float (10-K cover)

61.7Mshares outstanding as of Aug 7, 2026 · was 60.3M Mar 17, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

Date	Signal	Evidence	Score
Aug 12, 2026	▼ Shelf effective	EFFECT notice 2026-08-12 filing	21
Aug 10, 2026	▼ Going-concern language	“going concern periodic” language in 10-Q (10-Q) filed 2026-08-10 filing	29
Jul 20, 2026	▼ Holder rights modified	8-K Item 3.03 filed 2026-07-20 (accepted 16:00 ET) filing	30
Jun 30, 2026	▼ Near $5M MVLS floor	Public float $4,400,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing	27

Other forced raise setups

VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans